BFRIW | Biofrontera Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	0.0310 - 0.0310
52 Week Range	0.0310 - 0.0310
Beta	N/A
Implied Volatility	N/A
IV Rank	N/A
Day's Volume	3,322
Average Volume	N/A
Shares Outstanding	218,164,258
Market Cap	7,151,138
Sector	Healthcare
Industry	Drug Manufacturers - Specialty & Generic
IPO Date	N/A

Valuation
Profitability
Growth
Health
P/E Ratio	-0.02
Forward P/E Ratio	N/A
EPS	-1.30
1YR Price Target	N/A
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	83
Country	USA
Website	BFRIW

Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company offers Ameluz, a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. It also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.

BFRIW's peers: NTRBW, SBFMW, BEATW, BFRI, KTTAW, IINNW, BJDX, NRXPW

*Chart delayed

Analyzing fundamentals for BFRIW we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see BFRIW Fundamentals page.

Watching at BFRIW technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on BFRIW Technicals page.